Day One Biopharmaceuticals DAWN Q4 2025 Earnings EPS Miss Reflects RD Spend Amid PreRevenue Status Nextpower Inc NXT Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency MNPR Q1 2026 Earnings Surprise EPS Beat in PreRevenue Biotech RWTN Q1 2026 Earnings EPS Miss Pared by Positive Surprise but Stock Gains Amid Broader Sector Optimism CRVS Q1 2026 Earnings EPS Misses Estimates as PreCommercial Biotech Continues Pipeline Progress MIAX Q1 2026 Earnings EPS Surpasses Estimates by 98 Amid Stable Operations